CA2222981A1 - Promoter of the human endoglin gene and its use - Google Patents

Promoter of the human endoglin gene and its use Download PDF

Info

Publication number
CA2222981A1
CA2222981A1 CA002222981A CA2222981A CA2222981A1 CA 2222981 A1 CA2222981 A1 CA 2222981A1 CA 002222981 A CA002222981 A CA 002222981A CA 2222981 A CA2222981 A CA 2222981A CA 2222981 A1 CA2222981 A1 CA 2222981A1
Authority
CA
Canada
Prior art keywords
approx
promoter
nucleic acid
gene
acid construct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002222981A
Other languages
English (en)
French (fr)
Inventor
Wolff Graulich
Dirk Nettelbeck
Hans-Harald Sedlacek
Rolf Muller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Publication of CA2222981A1 publication Critical patent/CA2222981A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
CA002222981A 1997-02-06 1998-02-04 Promoter of the human endoglin gene and its use Abandoned CA2222981A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19704301.1 1997-02-06
DE19704301A DE19704301C1 (de) 1997-02-06 1997-02-06 Der Promotor des humanen Endoglingens und seine Verwendung für die Gentherapie

Publications (1)

Publication Number Publication Date
CA2222981A1 true CA2222981A1 (en) 1998-08-06

Family

ID=7819364

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002222981A Abandoned CA2222981A1 (en) 1997-02-06 1998-02-04 Promoter of the human endoglin gene and its use

Country Status (15)

Country Link
US (1) US6103527A (enExample)
EP (1) EP0857781A3 (enExample)
JP (1) JPH11178A (enExample)
KR (1) KR19980071084A (enExample)
CN (1) CN1196784C (enExample)
AR (1) AR011110A1 (enExample)
AU (1) AU736724B2 (enExample)
BR (1) BR9800563A (enExample)
CA (1) CA2222981A1 (enExample)
CZ (1) CZ289227B6 (enExample)
DE (1) DE19704301C1 (enExample)
HU (1) HUP9800247A3 (enExample)
PL (1) PL324688A1 (enExample)
RU (1) RU2230115C2 (enExample)
TR (1) TR199800168A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19704301C1 (de) * 1997-02-06 1998-03-26 Hoechst Ag Der Promotor des humanen Endoglingens und seine Verwendung für die Gentherapie
HUP9900956A2 (hu) 1998-04-09 2002-04-29 Aventis Pharma Deutschland Gmbh. Egyláncú, több antigéntkötőhely kialakítására képes molekulák, előállításuk és alkalmazásuk
DE60013586T2 (de) 1999-04-02 2005-02-03 Hisamitsu Pharmaceutical Co., Inc., Tosu Genexpressions-basensequenzen zur therapeutischen anwendung und heilmittel zur gentherapie
RU2295281C2 (ru) * 2005-04-20 2007-03-20 Федеральное государственное учреждение Научно-исследовательский институт детских инфекций, г.Санкт-Петербург Способ оценки тяжести инфекционного поражения цнс у детей
RU2297848C2 (ru) * 2005-05-11 2007-04-27 Александр Веньяминович Иткес Генно-инженерная конструкция vegf-ибмед (vegf-ibmed)
US20090136465A1 (en) 2007-09-28 2009-05-28 Intrexon Corporation Therapeutic Gene-Switch Constructs and Bioreactors for the Expression of Biotherapeutic Molecules, and Uses Thereof
EP2310507A4 (en) 2008-07-08 2013-03-20 David Gladstone Inst METHOD AND COMPOSITIONS FOR ANGIOGENIC MODULATION
EP2951306A4 (en) 2013-01-30 2016-07-27 Univ Nebraska COMPOSITIONS AND METHOD FOR TREATING COMPLICATIONS RELATED TO DIABETES

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466596A (en) * 1992-08-25 1995-11-14 Mount Sinai Hospital Corporation Tissue specific transcriptional regulatory element
GB9506466D0 (en) * 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
DE19704301C1 (de) * 1997-02-06 1998-03-26 Hoechst Ag Der Promotor des humanen Endoglingens und seine Verwendung für die Gentherapie

Also Published As

Publication number Publication date
EP0857781A2 (de) 1998-08-12
JPH11178A (ja) 1999-01-06
TR199800168A2 (xx) 1998-08-21
KR19980071084A (ko) 1998-10-26
RU2230115C2 (ru) 2004-06-10
CN1196784C (zh) 2005-04-13
HUP9800247A3 (en) 2002-11-28
AU736724B2 (en) 2001-08-02
CZ33298A3 (cs) 1998-08-12
US6103527A (en) 2000-08-15
HU9800247D0 (en) 1998-03-30
AU5293198A (en) 1998-08-13
HUP9800247A2 (hu) 1998-10-28
BR9800563A (pt) 1999-06-29
AR011110A1 (es) 2000-08-02
CZ289227B6 (cs) 2001-12-12
CN1203948A (zh) 1999-01-06
PL324688A1 (en) 1998-08-17
EP0857781A3 (de) 2001-05-16
DE19704301C1 (de) 1998-03-26
MX9800981A (es) 1998-08-30

Similar Documents

Publication Publication Date Title
Plowman et al. The amphiregulin gene encodes a novel epidermal growth factor-related protein with tumor-inhibitory activity
Wenger et al. The 5′ flanking region and chromosomal localization of the gene encoding human platelet membrane glycoprotein Ibα
Thomassin et al. Molecular cloning of two C/EBP-related proteins that bind to the promoter and the enhancer of the α 1-fetoprotein gene. Further analysis of C/EBPβ and C/EBPγ
JPH09505474A (ja) 翻訳エンハンサーｄｎａ
Ranganathan et al. Cloning of murine tissue factor and regulation of gene expression by transforming growth factor type beta 1.
US6143871A (en) IL-13 and IL-4 binding polypeptides
US5888765A (en) Endothelial-cell specific promoter
AU736724B2 (en) Promoter of the human endoglin gene and its use
Robb et al. Identification of a second murine interleukin-11 receptor α-chain gene (IL11Ra2) with a restricted pattern of expression
Hern et al. Collagen α1 (I) Gene Contains an Element Responsive to Tumor Necrosis Factor-α Located in the 5'Untranslated Region of Its First Exon
Ren et al. The major regulatory element upstream of the alpha-globin gene has classical and inducible enhancer activity
Hehlgans et al. Activation of transcription by binding of NF-E1 (YY1) to a newly identified element in the first exon of the human DR alpha gene.
Hewett et al. Cloning and Partial Characterization of the Humantie-2 Receptor Tyrosine Kinase Gene Promoter
MXPA98000981A (en) Promoter of human endoglin gene and his
EP1556412B1 (en) Promoter to il-18bp, its preparation and use
AU754272B2 (en) Adenoviral transfer vector for the gene transport of a DNA sequence
Smagur et al. Recombinant angioarrestin secreted from mouse melanoma cells inhibits growth of primary tumours
KR100419972B1 (ko) 링커 염기서열로 연결된 인간 ｖｅｇｆ의 돌연변이형동형이합체 유전자, 이를 포함하는 발현벡터, 이의형질전환체 및 단백질
HK1017713A (en) Promoter of the human endoglin gene and its use
JP2005312304A (ja) 新規インターフェロン制御因子活性化ポリペプチド及びそれをコードする核酸
Penny Structure and expression of the human erythropoietin receptor gene
HK1082510B (en) Promoter to il-18bp, its preparation and use

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued